Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04448106
Other study ID # CTX0020-002
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date September 25, 2023
Est. completion date August 15, 2026

Study information

Verified date April 2023
Source Celltex Therapeutics Corporation
Contact Jane Young
Phone 7135901000
Email jyoung@celltexbank.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 2 open-label, 6 arms (1 study group and 1 control group for each joint category), randomized control group clinical study with 300 subjects diagnosed with osteoarthritis of knees (n=100), hips (n=100) and shoulders (n=100). The study subjects will be evaluated for disease-associated severity according to symptoms, such as pain, mobility, daily active life, and functions using arthritis society established specific measurement tools related to the joints (KOOS and KSS for OA-knees: HOOS and HHS for OA-hips and ASES and CSS for OA-shoulders).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date August 15, 2026
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age above 18 years - Male or female - Subjects in study group must have banked AdMSCs at Celltex (already passed communicable disease screen tests for HIV, syphilis and Hepatitis B and C during banking stage) - Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures - Must be diagnosed as OA-knees, OA-hips, or OA-shoulders by radiographic criteria and physical examination. Exclusion Criteria: - Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start - Unwillingness or inability to comply with study procedures - Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc. - Clinically active malignant disease - Previous thrombotic disorder - History of known pulmonary embolism or known secondary anti-phospholipid syndrome - Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur-containing products (e.g., DMSO) - Major trauma or surgery within 14 days of study treatment start - Mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study - Alcohol, drug, or medication abuse within one year prior to study treatment start - Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study - Irreversible severe end-organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions - Patients or family history with a hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc. - History of long-term use of immunosuppressive agents - Organ transplants in the previous 6 months - Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study

Study Design


Intervention

Biological:
Celltex- AdMSCs
Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue

Locations

Country Name City State
United States Stanley C Jones Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Celltex Therapeutics Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of patients achieve visual analog scale (VAS) pain improvement above 30%, 50% and 70% from the baseline efficacy 12 months
Other Number of patient achieve Image (X-ray or MRI) improvement above 30%, 50% and 70% from the baseline efficacy 12 months
Primary the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects. safety 12 months
Primary Any organ damage or safety concerns determined by SMAC 20 blood test. Safety 12 months
Secondary Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients efficacy 12 months
Secondary Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients efficacy 12 months
Secondary Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients efficacy 12 months
Secondary Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients efficacy 12 months
Secondary Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients efficacy 12 month
Secondary Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients efficacy 12 months
Secondary changes in joint images (X-ray or MRI) from the baseline efficacy 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients Phase 2
Completed NCT02901964 - Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial N/A
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Terminated NCT02909257 - Motor-Sparing Femoral Nerve Block Dose Phase 4